drugset / Trial / NCT02651376

Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients

NCT02651376 ↗

Phase 1/2 Completed 20 enrolled Beijing 302 Hospital
NaSingle-groupOpen-labelTreatment

Summary

Combined antiretroviral therapy (cART) efficiently suppress viral replication in majority of AIDS patients. The morbidity and mortality of the disease has dramatically decreased over the past 20 years. However, chronic human immunodeficiency virus-1 (HIV-1) infection lead to profound immune defects in some advanced AIDS patients who often develop with severe opportunistic infections (OIs), severe cachexia and other deadly complications, which accounts for the major death group even under cART. Up-to-date, there are no effective immune interventions to restore host holistic immunity for advanced AIDS patients.

Timeline

Start
2015-09
Primary completion
2017-04
Completion
2017-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Allogeneic Adoptive Immune Therapy Cell therapy 2e+08 cells/kg Intravenous
Subject Allogeneic Adoptive Immune Therapy Cell therapy 3e+08 cells/kg Intravenous